Private Company Price Index (PCPI)
04 May 2022
PCPI Q1 2022: Deal volumes in Q1 return to pre-pandemic levels
573 deals were completed in Q1 of 2022, down 16.8% from volumes seen in Q4 (689). Volumes match the average number of deals completed in 2019, before the pandemic. Following a subdued start to the year, March was the busiest month in the quarter.
The decrease in overall deal volumes was driven by a 20% decline in trade activity. Private equity deals increased marginally by 6.3%.
DOWNLOAD THE LATEST PCPI REPORT
PCPI blog: Four reasons why investors should remain interested in Life Sciences & Pharmaceutical Services
The life sciences sector is sometimes seen as a little conservative and behind others in terms of embracing the digital age. However, the pandemic has really changed things; investment has poured in, and the sector has performed incredible feats of ingenuity in devising, developing, manufacturing, and distributing new vaccines in unprecedented timeframes in a very public spotlight.
Partners, Jamie Austin and Gurpal Ahluwalia outline reasons to consider investing in life sciences and the supporting pharmaceutical services.
READ OUR LATEST PCPI BLOG
Each quarter we collect data surrounding Enterprise Value (EV) to Earnings Before Interest Tax Depreciation and Amortisation (EBITDA) multiples. The Index tracks the EV to EBITDA multiples paid by trade and private equity buyers when purchasing UK private companies.
We examine this market data and compare it with historic data to identify key trends. We draw on our long experience of running the PCPI and our sector-specific expertise to predict future market trends.
ACCESS PREVIOUS PCPI EDITIONS